您的位置: 专家智库 > >

国家自然科学基金(30901719)

作品数:2 被引量:10H指数:2
相关作者:陈柳毕锋冷卫兵李黎博唐秋琳更多>>
相关机构:四川大学华西医院华西医科大学更多>>
发文基金:国家自然科学基金更多>>
相关领域:医药卫生更多>>

文献类型

  • 2篇中文期刊文章

领域

  • 2篇医药卫生

主题

  • 1篇增殖
  • 1篇真核
  • 1篇真核表达
  • 1篇真核表达质粒
  • 1篇质粒
  • 1篇生物学
  • 1篇生物学特性
  • 1篇气象
  • 1篇气象部门
  • 1篇胃癌
  • 1篇细胞
  • 1篇细胞系
  • 1篇耐药
  • 1篇耐药细胞
  • 1篇耐药细胞系
  • 1篇结肠
  • 1篇结肠癌
  • 1篇核表达
  • 1篇恶性
  • 1篇恶性表型

机构

  • 1篇华西医科大学
  • 1篇四川大学华西...

作者

  • 1篇李明星
  • 1篇李荣惠
  • 1篇袁丹丹
  • 1篇唐秋琳
  • 1篇李黎博
  • 1篇冷卫兵
  • 1篇毕锋
  • 1篇陈柳

传媒

  • 1篇癌症
  • 1篇四川大学学报...

年份

  • 1篇2013
  • 1篇2010
2 条 记 录,以下是 1-2
排序方式:
ARHI真核表达质粒对胃癌恶性表型的影响被引量:2
2013年
目的观察外源ARHI在胃癌细胞中过表达对胃癌细胞增殖、迁移以及侵袭的影响。方法构建pEGFP-ARHI表达载体,并通过lipofectamineTM2000将其转入ARHI低表达的胃癌细胞系MKN-28中作为实验组,空载质粒pEGFP-N1转入MKN-28作为空载组,未处理MKN-28细胞作为未处理组。通过荧光显微镜及Western blot检测外源ARHI的表达,采用增殖实验、损伤刮擦实验、体外侵袭实验(Transwell小室)分别检测过表达ARHI胃癌细胞MKN-28的增殖能力、侵袭和迁移能力的变化。结果 ARHI在胃癌细胞系MKN-28中表达较低,成功构建重组真核表达质粒pEGFP-ARHI并成功转染MKN-28细胞后,CCK8法检测显示,相对于空载组和未处理组,转染pEGFP-ARHI的实验组细胞增殖变慢(P<0.05),Transwell小室实验显示实验组细胞侵袭能力减弱(P<0.05),细胞划痕实验表明实验组细胞迁移能力减弱(P<0.05)。结论在ARHI低表达的胃癌细胞系MKN-28中表达重组质粒pEGFP-ARHI能够抑制细胞的增殖、侵袭和迁移能力。
李黎博唐秋琳李明星冷卫兵陈柳袁丹丹李荣惠毕锋
关键词:ARHIMKN-28增殖
结肠癌奥沙利铂耐药细胞系的建立及其生物学特性的研究(英文)被引量:8
2010年
Background and Objective:Chemotherapy is the main treatment for colon cancer,while multidrugresistance is the main reason for chemotherapy failure and tumor relapse.This study was to establish two oxaliplatinresistant colon cancer cell lines and evaluate their biological characteristics.Met hods:Oxaliplatin-resistant colon cancer cell lines SW620/L-OHP and lovo/L-OHP were established in vitro by continuous exposure to oxaliplatin(L-OHP) of low and gradually increased concentration.Growth curve,cross-resistance and resistance index of the oxaliplatin-resistant cell lines to various anti-cancer agents were determined by CCK8 assay.The expressions of P-glycoprotein(P-gp),multidrugresistance protein 1(MRP1) and MRP2 were detected by Western blot.Cell cycle distribution as well as the expression of CD133 and CD44 were measured by flow cytometry.Result s:It took 10 months to establish the SW620/L-OHP and LoVo/L-OHP cell lines with stable resistance to oxaliplatin.Cross-resistance to 5-fluorouracil,etoposide,cisplatin,vincristine and epirubicin but not to paclitaxel was observed.Longer doubling time,higher proportion of cells in G0/G1 phase and lower proportion in G2/M phase were observed in the two oxaliplatin-resistant cell lines compared with their parental cell lines.The expression of MRP2 in the oxaliplatin-resistant cells was up-regulated,while those of P-gp and MRP1 had no significant change.CD133 was overexpressed while CD44 level remained unchanged in SW620/L-OHP and LoVo/L-OHP cells.Conclusions:SW620/L-OHP and LoVo/L-OHP cell lines show a typical and stably resistant phenotype and may be used as research models.
刘桢邱萌唐秋琳
关键词:奥沙利铂生物学特性结肠癌CD44气象部门
共1页<1>
聚类工具0